01:09 , Aug 23, 2019 |  BC Innovations  |  Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
21:31 , May 28, 2019 |  BC Extra  |  Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million...
18:22 , May 7, 2019 |  BC Extra  |  Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence acalabrutinib as...
21:41 , Apr 19, 2019 |  BC Extra  |  Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
17:28 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain. The data follow...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
19:04 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
23:25 , Oct 24, 2018 |  BC Extra  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
18:45 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency. A...